tbuckley/cabot-search huggingface dataset:
Cell Adhesion: The Role of Titanium Surface Nanostructuring on Preosteoblast Morphology, Adhesion, and Migration (Adv. Healthcare Mater. 15/2017)
Authors: Yulia Zhukova, Christian Hiepen, Petra Knaus, Marc Osterland, Steffen Prohaska, John W. C. Dunlop, Peter Fratzl, Ekaterina V. Skorb
Journal: Advanced Healthcare Materials (2017)

A kaleidoscope of surface properties guides a kaleidoscope of cell dynamic behavior and communication with a nanoarchitectured support. In article number 1601244, Peter Fratzl and co-workers focus on the impact of different titania nanotopography on osteo-progenitor cell adhesion, stress fiber formation and migration.
Prebiotic galacto-oligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants
Authors: Daniela Paganini, Mary A Uyoga, Guus A M Kortman, Colin I Cercamondi, Diego Moretti, Tanja Barth-Jaeggi, Clarissa Schwab, Jos Boekhorst, Harro M Timmerman, Christophe Lacroix, Simon Karanja, Michael B Zimmermann
Journal: Gut (2017)

<h3>Objective</h3> Iron-containing micronutrient powders (MNPs) reduce anaemia in African infants, but the current high iron dose (12.5 mg/day) may decrease gut <i>Bifidobacteriaceae</i> and <i>Lactobacillaceae</i>, and increase enteropathogens, diarrhoea and respiratory tract infections (RTIs). We evaluated the efficacy and safety of a new MNP formula with prebiotic galacto-oligosaccharides (GOS) combined with a low dose (5 mg/day) of highly bioavailable iron. <h3>Design</h3> In a 4-month, controlled, double-blind trial, we randomised Kenyan infants aged 6.5–9.5 months (n=155) to receive daily (1) a MNP without iron (control); (2) the identical MNP but with 5 mg iron (2.5 mg as sodium iron ethylenediaminetetraacetate and 2.5 mg as ferrous fumarate) (Fe group); or (3) the identical MNP as the Fe group but with 7.5 g GOS (FeGOS group). <h3>Results</h3> Anaemia decreased by ≈50% in the Fe and FeGOS groups (p&lt;0.001). Compared with the control or FeGOS group, in the Fe group there were (1) lower abundances of <i>Bifidobacterium</i> and <i>Lactobacillus</i> and higher abundances of <i>Clostridiales</i> (p&lt;0.01); (2) higher abundances of virulence and toxin genes (VTGs) of pathogens (p&lt;0.01); (3) higher plasma intestinal fatty acid-binding protein (a biomarker of enterocyte damage) (p&lt;0.05); and (4) a higher incidence of treated RTIs (p&lt;0.05). In contrast, there were no significant differences in these variables comparing the control and FeGOS groups, with the exception that the abundance of VTGs of all pathogens was significantly lower in the FeGOS group compared with the control and Fe groups (p&lt;0.01). <h3>Conclusion</h3> A MNP containing a low dose of highly bioavailable iron reduces anaemia, and the addition of GOS mitigates most of the adverse effects of iron on the gut microbiome and morbidity in African infants. <h3>Trial registration number</h3> NCT02118402.
Response Assessment of 223Ra Treatment
Authors: Ana María García Vicente, Ángel Soriano Castrejón, Ruth Alvarez Cabellos, Belén Sanchez Gil, Nicolás Mohedano Mohedano
Journal: Clinical Nuclear Medicine (2017)

We present 3 cases of patients with castration-resistant prostate cancer and bone metastases treated with Ra, belonging to our prospective and multicenter ChoPET-Rad study. All patients underwent clinical, hematological, and biochemical monitoring between each Ra administration. Initial and follow-up F-fluorocholine PET/CT and Tc-biphosphonate bone scintigraphy were performed previously and after the third Ra administration. Both techniques correctly established the response to treatment, in agreement to the biochemical response, although differences in the disease expression (concordant and discordant patterns) were found because of the different radiotracer biodistribution and molecular information derived from them.
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, Susan Darlow
Journal: Journal of the National Comprehensive Cancer Network (2017)

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.
Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets
Authors: Alyssa Bouska, Chengfeng Bi, Waseem Lone, Weiwei Zhang, Ambreen Kedwaii, Tayla Heavican, Cynthia M. Lachel, Jiayu Yu, Roberto Ferro, Nanees Eldorghamy, Timothy C. Greiner, Julie Vose, Dennis D. Weisenburger, Randy D. Gascoyne, Andreas Rosenwald, German Ott, Elias Campo, Lisa M. Rimsza, Elaine S. Jaffe, Rita M. Braziel, Reiner Siebert, Rodney R. Miles, Sandeep Dave, Anupama Reddy, Jan Delabie, Louis M. Staudt, Joo Y. Song, Timothy W. McKeithan, Kai Fu, Michael Green, Wing C. Chan, Javeed Iqbal
Journal: Blood (2017)
シグナル伝達アダプターTRAF1は,Toll様受容体シグナル伝達を負に調節し,このことがリウマチ性疾患におけるその役割の基礎にある
Authors: Abdul‐Sater Ali A, Edilova Maria I, Clouthier Derek L, Mbanwi Achire, Kremmer Elisabeth, Watts Tania H
Journal: Nature Immunology (2017)
Improvised vs Commercial Tourniquets
Authors: Matthew J. Levy, Craig Goolsby, Alexander L. Eastman
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
自閉症スペクトラム障害:集団の参照試料を用いて神経発達障害におけるde novoのタンパク質短縮型バリアントの役割を詳細に解析する
Authors: Kosmicki Jack A, Samocha Kaitlin E, Howrigan Daniel P, Lek Monkol, Karczewski Konrad J, Neale Benjamin M, Macarthur Daniel G, Robinson Elise B, Daly Mark J, Slowikowski Kamil, Sanders Stephan J, Cutler David J, Devlin Bernie, Roeder Kathryn, Buxbaum Joseph D, Wall Dennis P
Journal: Nature Genetics (2017)
G蛋白質共役カルシウム感知受容体はMTA誘導生物活性の重要なメディエーターである【Powered by NICT】
Authors: Kim Jin Man, Choi Seulki, Kwack Kyu Hwan, Kim Sun-Young, Lee Hyeon-Woo, Park Kyungpyo
Journal: Biomaterials (2017)
OVERTRAINING AS A RISK FACTOR FOR ANTERIOR CRUCIATE LIGAMENT RUPTURE IN FEMALE BASKETBALL PLAYERS
Authors: Tamara Stojmenovic, Tatjana Malic, Milica Vukasinovic-Vesic, Marija Andjelkovic, Nenad Dikic
Journal: British Journal of Sports Medicine (2017)

Background High incidence of anterior cruciate ligament (ACL) tears among female basketball players requires a proper understanding of the risk factors in order to reduce the number of these severe events. Objective It was hypothesized that athletes involved in professional level of basketball and more than 10 hours of training per week at young age are exposed to greater risk of ACL rupture due to overtraining. Design Non-experimental correlation retrospective study was performed. Setting In order to collect data Serbian female basketball players, from both domestic and European professional teams, were contacted. Patients (or Participants) A total of 108 female basketball players were included in the study (age 26.26±6.8). Interventions (or Assessment of Risk Factors) The questionnaire regarding the involvement in a professional level of basketball and hours/week of training at younger age was administrated to participants. The logistic regression method was used in order to calculate the odds ratio confidence interval (O. R.). Main Outcome Measurements The athletes exposed to high intensity and frequency of training had grater odds of getting ACL rupture. Results 43 out of 108 athletes reported ACL injury at the age of 18.25±3.12. Those involved in professional level of basketball had an odds of ACL injury about 9.25 times greater than those who competed only for their age group (OR 9.2503; p=0.0001). The ones exposed to more than 10 hours of training per week had an odds of ACL injury about 7.54 greater than those with less training hours (O R 7.5374; p=0.0002). Conclusions Playing basketball at a professional level at younger age can lead to overtraining and consequently an increased incidence of ACL ruptures in female basketball players. Accordingly, intensity and frequency of training must be adapted to both chronological and biological age of young athletes in order to prevent this serious injury.
A Woman With Purple Macules on the Legs
Authors: Jeffrey M. Cohen, Alisa N. Femia, Roger S. Ho
Journal: JAMA (2017)

A 30-year-old woman had widespread, erythematous, purpuric macules and papules on the abdomen and extremities. A skin punch biopsy showed extravasated erythrocytes, a neutrophilic infiltrate, fibrinoid necrosis, and broken-down neutrophils releasing nuclear debris. What would you do next?
Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis
Authors: Lucile Sesé, Hilario Nunes, Vincent Cottin, Shreosi Sanyal, Morgane Didier, Zohra Carton, Dominique Israel-Biet, Bruno Crestani, Jacques Cadranel, Benoit Wallaert, Abdellatif Tazi, Bernard Maître, Grégoire Prévot, Sylvain Marchand-Adam, Stéphanie Guillot-Dudoret, Annelyse Nardi, Sandra Dury, Violaine Giraud, Anne Gondouin, Karine Juvin, Raphael Borie, Marie Wislez, Dominique Valeyre, Isabella Annesi-Maesano
Journal: Thorax (2017)

Introduction Idiopathic pulmonary fibrosis (IPF) has an unpredictable course corresponding to various profiles: stability, physiological disease progression and rapid decline. A minority of patients experience acute exacerbations (AEs). A recent study suggested that ozone and nitrogen dioxide might contribute to the occurrence of AE. We hypothesised that outdoor air pollution might influence the natural history of IPF. Methods Patients were selected from the French cohort COhorte FIbrose (COFI), a national multicentre longitudinal prospective cohort of IPF (n=192). Air pollutant levels were assigned to each patient from the air quality monitoring station closest to the patient’s geocoded residence. Cox proportional hazards model was used to evaluate the impact of air pollution on AE, disease progression and death. Results Onset of AEs was significantly associated with an increased mean level of ozone in the six preceding weeks, with an HR of 1.47 (95% CI 1.13 to 1.92) per 10 µg/m 3 (p=0.005). Cumulative levels of exposure to particulate matter PM 10 and PM 2.5 were above WHO recommendations in 34% and 100% of patients, respectively. Mortality was significantly associated with increased levels of exposure to PM 10 (HR=2.01, 95% CI 1.07 to 3.77) per 10 µg/m 3 (p=0.03), and PM 2.5 (HR=7.93, 95% CI 2.93 to 21.33) per 10 µg/m 3 (p&lt;0.001). Conclusion This study suggests that air pollution has a negative impact on IPF outcomes, corroborating the role of ozone on AEs and establishing, for the first time, the potential role of long-term exposure to PM 10 and PM 2.5 on overall mortality.
Resection of breast cancer brain metastases: A single institution experience.
Authors: Claire Brady, Richard Martin Bambury, Jodie E Battley, Susan Murray, Seamus O'Reilly, Derek G Power, Eugene J. Moylan, Niamh Bermingham, Catherine Keohane, George Karr, Charles Marks, Michael GJ O' Sullivan
Journal: Journal of Clinical Oncology (2012)

e11569 Background: Resection of a single brain metastasis (SBM) in metastatic cancer has been shown to improve overall survival (OS). A previously reported series from MD Anderson of breast cancer patients undergoing SBM resection reported a median overall survival of 19 months. We report our experience of SBM resection for breast cancer. Methods: Retrospective observational study of patients who underwent resection of SBM from breast cancer brain in a tertiary referral centre from 2000-2011. Results: 20 patients underwent SBM resection from 2000-2011. All patients received WBRT after surgery. 2 patients had progressive metastatic disease presenting as brain metastases. Median time from original breast cancer diagnosis to development of SBM was 53 months (range:1-286months). 9 patients had solitary brain metastases (no metastases elsewhere) and 11 patients had synchronous metastases elsewhere. Regarding the primary breast tumour: 41% of patients were ER+, 57% were HER2+ and 25% were triple negative. 1 patient had discordance of ER status between the primary tumour and brain metastasis (changed from ER- to ER+). Median overall survival was 9 months (95% CI: 5-18 months) with 1 year OS of 50%, 2 year OS of 15% and 3 year OS of 5%. Patients treated between 2006-2011 had better median OS than those treated 2000-2005(18 months vs 6 months – p-value not significant). Patients with a solitary brain metastasis had better median OS than those with synchronous extracranial disease (13 months vs 6 months – p-value not significant). An additional 2 patients underwent craniotomy for presumed breast cancer metastasis but histology revealed glioblastoma multiforme. Conclusions: We report on a cohort of patients undergoing metastatectomy for single brain metastasis from breast cancer. Median OS was 9 months but there was a trend towards better survival in patients treated in recent years when compared with those treated from 2000-2005. Improved systemic therapies may account for this difference. Also of note 2 patients undergoing resection for presumed brain metastases were found to have GBM, highlighting the role of tissue diagnosis in patients presenting with a solitary brain lesion.
Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
Authors: Carlos A. Ramos, Brandon Ballard, Huimin Zhang, Olga Dakhova, Adrian P. Gee, Zhuyong Mei, Mrinalini Bilgi, Meng-Fen Wu, Hao Liu, Bambi Grilley, Catherine M. Bollard, Bill H. Chang, Cliona M. Rooney, Malcolm K. Brenner, Helen E. Heslop, Gianpietro Dotti, Barbara Savoldo
Journal: Journal of Clinical Investigation (2017)

Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. However, adverse events, mainly mediated by the toxin component of the conjugated antibodies, cause treatment discontinuation in many patients. Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment antitumor activity.We conducted a phase I dose escalation study in which 9 patients with relapsed/refractory HL or ALCL were infused with autologous T cells that were gene-modified with a retroviral vector to express the CD30-specific CAR (CD30.CAR-Ts) encoding the CD28 costimulatory endodomain. Three dose levels, from 0.2 × 108 to 2 × 108 CD30.CAR-Ts/m2, were infused without a conditioning regimen. All other therapy for malignancy was discontinued at least 4 weeks before CD30.CAR-T infusion. Seven patients had previously experienced disease progression while being treated with brentuximab.No toxicities attributable to CD30.CAR-Ts were observed. Of 7 patients with relapsed HL, 1 entered complete response (CR) lasting more than 2.5 years after the second infusion of CD30.CAR-Ts, 1 remained in continued CR for almost 2 years, and 3 had transient stable disease. Of 2 patients with ALCL, 1 had a CR that persisted 9 months after the fourth infusion of CD30.CAR-Ts. CD30.CAR-T expansion in peripheral blood peaked 1 week after infusion, and CD30.CAR-Ts remained detectable for over 6 weeks. Although CD30 may also be expressed by normal activated T cells, no patients developed impaired virus-specific immunity.CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted.ClinicalTrials.gov NCT01316146.National Cancer Institute (3P50CA126752, R01CA131027 and P30CA125123), National Heart, Lung, and Blood Institute (R01HL114564), and Leukemia and Lymphoma Society (LLSTR 6227-08).
Adam Lothian Turnbull
Authors: Colin G Barnes, Brian T Colvin
Journal: BMJ (2017)

Adam Lothian Turnbull was born in Woking, Surrey, the fourth child of Hubert Maitland Turnbull DM FRCP FRCPath FRS and Catherine Nairne Arnold (nee Baker). His father had qualified in medicine at Oxford and the London Hospital Medical College in 1902, became director of the institute of pathology (the Bernhard Baron institute) at the London in 1906, and was subsequently the first professor of morbid anatomy at the University of London.

Adam’s ancestry was Scottish, although he and his siblings grew up in England. He was educated at Winchester; Magdalen College, Oxford; and the London Hospital Medical College. At Oxford his love of music, especially classical music, developed. He also participated in amateur dramatics, both backstage and as a leading member of the cast. He spent three years at Oxford gaining First BM and BA Physiology and, in September 1944, moved to the London Hospital Medical College for clinical studies at both the London Hospital in Whitechapel and its annexe at Brentwood. As an undergraduate he became involved in the production of the London Hospital Gazette , then a student publication. He also took part in the annual Christmas show, first on stage, then as director. After qualifying he led the part of the show presented by the resident house staff.

After qualifying in 1947 he became house physician to the medical unit, directed by Clifford Wilson, which included responsibility for the rheumatology beds under Will Tegner and …
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER+/HER2- metastatic breast cancer (MBC).
Authors: Antonio Llombart-Cussac, Meritxell Bellet, Pilar Zamora, Manuel Ruiz, Joseph Gligorov, Serena Di Cosimo, Peter Schmid, Shaheenah Dawood, Henri Roche, Frederic Marme, Elena Aguirre, Javier Cortes
Journal: Journal of Clinical Oncology (2016)

TPS625 Background: Palbociclib (P) is a cyclin-dependent kinase inhibitor approved for the treatment of ER+/HER2- locally advanced (LA) or MBC and, in combination with endocrine therapy, was shown to be superior, in terms of PFS, to endocrine therapy alone in both a phase II trial comparing P+letrozole (L) to L alone (PALOMA-1) as well as in a phase III trial comparing P+ fulvestrant (F) to F alone (PALOMA-3). In the phase II FIRST study PFS was greater in the high-dose F (HDF) arm compared to anastrozole (A) as 1L therapy for ER+ MBC. The phase III FALCON study has recently completed accrual and compares HDF to A as 1L treatment. With two new (L+P and HDF) standards of care shaping up as 1L endocrine therapy for ER+/Her2- LA/MBC, exploring the combination of P+HDF in the 1L setting seems mandatory. Methods: The PARSIFAL phase II study is an open-label, randomized, controlled, multicenter study with the primary aim of assessing 1-year PFS of P+HDF vs. P+L in women with ER+ LA/MBC. 304 eligible pts will be enrolled in 53 centers and 9 countries (Europe and Middle East). Pts must be postmenopausal women > 18 years old, an ECOG score ≤ 2, and histologically confirmed recurrent ER+/HER2- LA/MBC. Pts may not have received prior chemotherapy for LA/MBC and are randomized to receive 125 mg capsules of P taken once daily from D1 to D21 of every 28D cycle together with either HDF 500 mg/5mL i.m. injection administered on D1 (Cycle 1 loading dose also requires D14 administration also on) or 2.5 mg tablets of L once daily from D1 to D28. Treatment is given until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. For both combinations, secondary objectives are to: evaluate safety and tolerability; compare times to progression (TTP); and compare overall survival (OS) and clinical response results. The trial is in progress (start: Aug 2015, end: Jul 2017) and 62 pts have been accrued in 4 countries. A series of complementary prospective molecular studies are planned in order to evaluate predictive/prognostic biomarkers to P and endocrine therapy. Clinical trial information: 2014-004698-17.
Renal functional reserve and pregnancy outcomes
Authors: Abhilash Koratala, Amir Kazory
Journal: Kidney International (2017)

We read with great interest the article by Webster et al. in which they discussed the increased risk of adverse pregnancy outcomes in patients with mild renal dysfunction, even in the absence of hypertension, proteinuria, or systemic disease.1,2 The authors argued that the degree of renal function impairment in those individuals might have been underestimated because of the error proneness of currently used equations for assessment of glomerular filtration rate (GFR).